Aatru Medical Awarded 1st Place in “Oral Abstracts” at SAWC Spring 2024 Symposium

CLEVELAND–(BUSINESS WIRE)–Aatru Medical, LLC announced that it was awarded 1st Place in Oral Abstracts at the 2024 Spring symposium hosted by the Society for Advanced Wound Care (SAWC). Aatru’s Oral Abstract detailed the clinical evaluation of their new, single-use negative pressure wound therapy for surgical incision applications, the NPSIMS™.




The Oral Abstracts are selected by committee from hundreds of submissions by global medtech companies and leading research institutions. The five highest-scoring submissions were selected for podium presentations, including Aatru. Its Chief Medical Officer, Dr. Jeffrey Ustin, a practicing trauma surgeon, delivered the presentation.

The abstract describes the results of Aatru’s first in-human clinical study conducted at two premier hospitals in New Zealand. The NPSIMS™ was applied across multiple surgical incision types, including spine, shoulder and plastic surgery.

Dr. Ustin noted, “It was an honor to represent the Aatru team at SAWC and bring attention to the success of our first in-human use of NPSIMS™. The product’s simplicity and elegance make it easy to use, friendly to the patient, and it is quite effective due to the system’s unique design and mode of action.”

The NPSIMS™ uses neither electrical or mechanical components, but instead utilizes a novel micro solid-state chemical reaction to deliver negative pressure to the incision site. Unlike other negative pressure wound therapy (NPWT) products on the market, the NPSIMS™ was designed specifically for surgical incisions.

About NPWT for closed surgical incisions:

Several post-operative wound complications are common following surgical procedures. NPWT is recognized for the management of open wounds, and in the last several years has been applied to closed surgical incisions. Compared with standard postoperative dressings, NPWT significantly reduces the rate of wound infection, seroma, and dehiscense. The global market opportunity for NPWT in the incision market is approximately $14B annually, with single-digit market penetration to date.

About Aatru Medical:

Aatru is a privately held medical device company focused on disrupting the surgical incision market with its FDA-cleared NPSIMS™, a simple, disposable, single-use, and low-cost NPWT device. Its patented design circumvents the need for electromechanical pumps, batteries and a canister. More information is available at www.aatru.com.

Contacts

Tom Lash

Aatru Medical, LLC Chief Operating Officer

216-303-6063

[email protected]

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.